Among the patients with variant TP53 LFS who developed cancer (n = 49), 38.8% (19/49) of the patients had a second germline variant in a known cancer predisposition or cancer-associated gene (class 1–3; Fig. 2E; Supplementary Table S5A–S5D). Here, TP53 is linked to cancer.